Topical Interferon Gamma for Macular Edema Secondary to Uveitis
Completed · Phase 1/Phase 2
Conditions studied: Anterior Uveitis, Uveitis
In brief
The objective of this study is to investigate the safety and efficacy of ocular instillations of interferon gamma-1b as a potential treatment for cystoid macular edema (CME) secondary to uveitis.
Key facts
- Study ID
- NCT01376362
- Run by
- National Eye Institute (NEI)
- People needed
- 5
- Starts
- 2011-06-01
- Expected to finish
- 2012-03-01
- Last updated by the study team
- 2012-10-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participant must be 18 years of age or older.
- Participant must understand and sign the protocol's informed consent document.
- Participant has a diagnosis of CME (central thickness of >275 microns on OCT and/or disruption of foveal contour) secondary to uveitis in at least one eye (the study eye).
- Participant is willing to comply with the study procedures and is expected to be able to return for all study visits.
- Participant has visual acuity of 20/400 or better in the study eye.
- Female participants of childbearing potential must not be pregnant or breast-feeding.
- Both female participants of childbearing potential and male participants able to father a child must agree to practice two acceptable forms of contraception during the study and for six weeks following the last administration of investigational product. Acceptable methods of contraception include hormonal contraception (i.e., birth control pills, injected hormones dermal patch or vaginal ring), intrauterine device, barrier methods with spermicide (diaphragm with spermicide, condom with spermicide) or surgical sterilization (hysterectomy, tubal ligation or vasectomy).
You may not qualify if…
- Participant is unable to tolerate the ocular instillations or follow study procedures.
- Participant has a significant active infection (an infection requiring treatment as determined by the medical team) that in the principal investigator's best medical judgment would preclude participation.
- Participant has multiple sclerosis (MS), as interferon gamma may cause MS exacerbations.
Where it is running
- National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.